mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

NCT03464968 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Biliary Cancer Metastatic

Interventions

DRUG: Oxaliplatin,5FU, leucovorin
DRUG: irinotecan,5FU, leucovorin

Sponsor

Seoul National University Bundang Hospital